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Abstract
Background. Pregnancy-induced hypertension (PIH) is a significant health issue in pregnancy, complicating 7–10% 
of pregnancies. L-arginine is an important mediator of vasodilation with a potential preventative role in pregnan-
cy-related hypertensive diseases. 
Aim of the study. The aim of the present study was to assess the differences in plasma L-arginine concentrations in 
physiological pregnancies and pregnancies complicated with hypertension in the third trimester. 
Material and methods. Plasma concentration of L-arginine was determined by ion-exchange chromatography in 
210 pregnant women (25–41 weeks of gestation). Plasma L-arginine concentration was expressed in μmol/cm3. 
Results. The mean L-arginine concentration was significantly higher in physiological pregnancy (0.102) than in 
the PIH group (0.034). The analysis of plasma L-arginine concentration in the subgroups of third trimester showed 
that L-arginine concentration in the PIH group decreased with increasing stage of pregnancy (25–34 hbd — 0.051; 
35–38 hbd — 0.03; 39–41 hbd — 0.02). L-arginine concentration in physiological pregnancies was the same in 
all subgroups (0.1). 
Conclusions. L-arginine may have a role in the prevention and treatment of pregnancy-induced hypertension. 
Further well-designed and adequately powered research is warranted.
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Introduction
Pregnancy-induced hypertension (PIH) is a preg-
nancy-specific hypertensive disorder, which can com-
plicate 7–10% of pregnancies [1, 2]. The pathophys-
iology of hypertension and proteinuria in pregnancy, 
known as PIH, remains largely undiscovered. Hy-
pertensive disorders of pregnancy contribute signifi-
cantly to both perinatal and maternal mortality and 
morbidity on global scale [3–5]. More than 30 years 
ago, Dr. Leon Chesley, an expert in the field of hyper-
tension in pregnancy, divided the most likely causative 
factors into four major categories: placental, renal, 
immunologic and dietary [6]. According to Saczko et 
al. [1], one of the PIH causes is excessive production 
of free radicals that induce arterial vasoconstriction. 
The other factors predisposing pregnant women to 
PIH include multiple pregnancy, foetal male gender, 
young maternal age (under 18 years of age in primi-
paras), advanced maternal age (over 40 years of age in 
multiparas), obesity, genetic load, chronic stress and 
excess sodium in diet [3–5]. However, PIH also oc-
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curs in pregnant women without the above-mentioned 
factors. Therefore, Skoczyńska et al. [2] believe that 
further research on this subject is needed. 
PIH is one of the most serious obstetric compli-
cations. Despite intensive studies carried out in many 
centres worldwide, the aetiopathogenesis of PIH has not 
been explained. It is evident that there is abnormal pla-
centation and defective trophoblast invasion resul ting 
in the utero-placental unit being under perfused [1]. 
These phenomena are associated with ischaemia and 
subsequent hypoxia leading to endothelial damage 
and production of vasoactive factors, which promote 
vasoconstriction. In response to that, nitric oxide is 
synthesized from the amino acid L-arginine [1, 7].
Under physiological conditions, endothelial cells 
secrete a number of active metabolites, which indi-
rectly or directly affect proper vascular contraction and 
relaxation. This leads to imbalance, predominantly in 
the prostacyclin and nitric oxide/thromboxane and 
endothelin system [8]. In pregnant women with PIH, 
an increase in thromboxane concentration (TXA2, 
Thromboxane A2) in relation to prostacyclin (PGI2, 
Prostacyclin) is observed, which induces increased va-
soconstriction, damage to and aggregation of blood 
platelets as well as reduced blood flow via the spiral ar-
teries. Physiologically, prostacyclin is a vasodilator and 
its high concentration determines proper trophoblast 
invasion into the walls of spiral arteries. Thromboxane, 
being its antagonist, strongly contracts vessels and 
increases platelet aggregation [8, 9]. 
Nitric oxide (NO) has a potent vasodilator effect, 
which is involved in inhibition of thromboxane pro-
duction, platelet aggregation and stimulation of pros-
tacyclin production [10–12]. Thanks to its properties, 
it plays a significant role in obstetric procedures like 
delivery, cervical ripening, intrauterine growth retarda-
tion and occurrence of PIH [13]. During pregnancy, 
the blood vessels undergo adaptive changes due to 
blood volume gain, reduced vascular tolerance and 
increased cardiac output, which lead to an increase 
in NO production. The most important NO donor 
is L-arginine. In the absence of L-arginine, gestatio-
nal hypertension develops. Facchinetti et al. [14] have 
demonstrated that L-arginine supplementation could 
significantly decrease blood pressure in PIH women.
Arginine (2-amino-5-guanidinopentanoic acid; 
L-ARG) is a semi-essential amino acid, physiologically 
active in its L-form, which is synthesized by endothe- 
lial cells and excreted with urine in vivo [15]. L-argi-
nine has been well recognized as a drug to treat vari-
able diseases and symptoms, as well as a dietary tonic. 
L-arginine is the substrate of NO, a potent vasodilator, 
which may play a major role in regulating blood pres-
sure [16]. Ścibor and Czeczot [15] and Wu et al. [17] 
believe that the main sources of L-arginine in the body 
are food, intracellular protein degradation and protein 
endogenous synthesis. An adult consumes about 5.4 g 
of L-arginine a day [18, 19], and about 50% of dietary 
L-arginine gets to the cardiovascular system [18, 20]. 
Moreover, 5 to 15% of plasma L-arginine in adults is 
endogenously synthesized from citrulline. The total 
plasma concentration of L-arginine depends on the 
developmental stage of an individual and diet, and 
ranges from 95 to 250 μmol/l [19, 20]. 
Ścibor and Czeczot [15] have demonstrated that 
L-arginine is used for the synthesis of proteins, urea, 
creatinine, proline, polyamines and NO. It is me-
tabolized to ornithine and urea in the urea cycle in 
the liver [18, 21]. In the kidneys and pancreas, it is 
a substrate in the synthesis of guanidoacetate, which 
is subsequently converted into creatinine [20, 21]. 
Moreover, L-arginine plays a special role in the car-
diovascular system, where as a source of NO it affects 
vasodilation. Continuous synthesis of NO in the en-
dothelium prevents the development of hypertension 
and other vascular diseases [15, 22]. Relaxation of 
vascular smooth muscles in response to NO effects 
is associated with the activity of cGK Ia (a protein 
kinase G isoform) and the muscle tone is regulated by 
phosphorylation of the myosin light chain. The final 
stage of NO action is lack of phosphorylation of the 
myosin light chain leading to relaxation of vascular 
smooth muscles [23, 24].
Wu and Meininger [25] as well as Wu and Morris 
[20] believe that the major source of L-arginine for NO 
synthesis in the vascular endothelial cells is extracellular 
L-arginine in blood plasma whose 54% is used for the 
synthesis of NO; the remaining amount originates from 
endogenous sources. Released from the vascular endo-
thelium, NO diffuses not only to the muscles but also to 
the lumen of blood vessels where it binds haemoglobin 
in the erythrocytes. The findings reported by Davisa et 
al. [26] and Moncada et al. [27] indicate that haemoglo-
bin can be one of the crucial stores of NO in the body. 
Further studies on this issue are likely to confirm that 
NO release from haemoglobin is possible, which would 
suggest that NO can act longer than several seconds and 
not only at the site of its synthesis [26, 27].
Administration of L-arginine seems to improve 
uterine-placental circulation and decrease maternal 
blood pressure [28]. Therefore, L-arginine supplemen-
tation might be a new therapeutic option and its plas-
ma level a new diagnostic option in quick diagnosis 
and appropriate treatment of PIH. 
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Objective
The aim of the present study was to assess the differ-
ences in plasma L-arginine concentrations in physio-
logical pregnancies and pregnancies complicated with 
hypertension in the third trimester.
Material and methods
Patients
The study involved 210 pregnant women, 25–41 
weeks of gestation, managed in the Chair and De-
partment of Obstetrics and Pathology of Pregnancy, 
Medical University of Lublin and Department of Gy-
naecology and Obstetrics with Admission Room of 
the Cardinal Wyszyński Regional Specialist Hospital 
in Lublin in the years 2010–2014. The overall number 
of women was divided into 2 groups: study group and 
control group. 
Women in the control group (n = 105) did not 
take any drugs that could affect the cardiovascular 
system and had blood pressure within normal limits 
(120/80 mm Hg). The mean age of women was 28.6 
years, height — 165.93 cm, body weight — 84.11 
kg, systolic blood pressure (SBP — 119.54 mm Hg 
and diastolic blood pressure (DBP) — 77.17 mm Hg. 
Women in the study group (n = 105) had elevat-
ed blood pressure (> 140/90 mm Hg) and no con-
comitant diseases that could increase blood pressure 
(e.g. diabetes). The mean age in this group was 32.11 
years, height — 163.01 cm, body weight — 96.48 kg, 
SBP — 162.98 mm Hg and DBP — 97.67 mm Hg. 
According to the recommendations of the European 
Society of Hypertension (ESH) and the European 
Society of Cardiology (ESC), blood pressure was mea-
sured twice at a 6-hour interval in a sitting position 
using an electronic sphygmomanometer [29, 30]. To 
obtain detailed data, women in the study and control 
groups were divided into 3 subgroups: 25–34, 35–38, 
39–41 hbd, 35 cases each. 
Experimental procedures were approved by the 
Bioethical Commission of the Medical University of 
Lublin, Poland (No KE-0254/223/2010). All women 
accepted the study protocol and gave written informed 
consent for participation.
Biochemical analyses
The study material was venous blood collected in 
the fasting state from women with physiological preg-
nancies and pregnancies complicated with hyperten-
sion, 9 ml, to the test-tubes containing lithium hepa-
rin (aspiration-vacuum systems, Sarstedt, Germany). 
The plasma from each blood sample was collect-
ed immediately after centrifugation at 4000 × g for 
10 min and then stored at –80°C until analysis. For 
L-arginine concentration measurements, plasma was 
deproteinised with 6% sulphosalicylic acid in lith-
ium-citrates buffer (pH = 2.6) and centrifuged at 
12000 × g for 20 min. The obtained plasma was used 
for L-arginine determination in an ion-exchange chro-
matography (INGOSAAA-400 apparatus for auto-
matic analysis of amino acids, Ingos Corp., Prague, 
Czech Republic). Amino acids were separated using 
the analytical column OSTION LG FA and identified 
in comparison to the standards provided by INGOS 
Corp. The original software MIKRO version 1.8.0 
(INGOS) was used for amino acid determinations. All 
the tests were performed in duplicate.
Plasma L-arginine concentration was expressed in 
μmol/cm3.
Statistical analysis
Statistical analyses were performed using Statistica 
v. 10.0 software (StatSoft, USA). Data were presented 
as a mean and standard deviation (SD). The distri-
bution of quantitative parameters was assessed using 
the Shapiro-Wilk W test. All quantitative parame-
ters were characterised by skew distribution; there-
fore, non-parametric tests were applied to evaluate 
inter-subgroup significant differences. Two indepen-
dent groups were compared using the Mann-Whitney 
U test. Inter-quantitative parameter correlations were 
assessed by Spearman’s rank correlation. 
The differences between mean values were consid-
ered as statistically significant at p < 0.05.
Results
The mean L-arginine concentration was signifi-
cantly higher in the control group of pregnancy than 
in PIH group. Results are presented in Table I and 
Figure 1.
Analysis of L-arginine plasma concentration in the 
subgroups of third trimester showed that L-arginine 
concentration in the PIH group decreased with in-
creasing stage of pregnancy (Fig. 2). L-arginine con-
centration in control pregnancies was the same in all 
subgroups — 0.1 μmol/cm3.
Analysis of correlations between L-arginine 
concentration, systolic and diastolic pressure in 
PIH-complicated pregnancies demonstrated a weak 
association between L-arginine concentration and 
SBP (Tab. II).
arterial hypertension 2016, vol. 20, no. 3
116 www.ah.viamedica.pl
Figure 2. L-arginine plasma concentration in the PIH group, in the 
subgroups of third trimester
Table I. Plasma concentration of L-arginine in the control and PIH group in the third trimester of pregnancy 
Parameter
Mean ± SD
P value
Control group (n = 105) PIH group (n = 105)
L-ARG [μmol/cm3] 0.102 ± 0.013 0.034 ± 0.014 < 0.00005
Table II. Correlation between plasma L-arginine concentration in the study group versus systolic and diastolic pressure
PIH group (n = 105)
R P R P
L-ARG 
& SBP –0.21 0.032
L-ARG 
& DBP –0.045 0.651
Figure 1. Plasma concentration of L-arginine in the control and PIH 
group in the third trimester of pregnancy
Discussion
It is well known that hypertensive disorders in 
pregnancy are an important cause of maternal and 
neonatal mortality. The main features in PIH include 
developing systolic blood pressure (SBP) ≥ 140, or dia-
stolic blood pressure (DBP) ≥ 90, and proteinuria of 
0.3 grams or greater in a 24-hour urine specimen after 
20 weeks of gestation in a woman who was previously 
normotensive. Hypertension is generally the earliest 
physical abnormality seen in PIH and is the most 
important clinical clue to the presence of diseases [31].
Cnossen et al. [32] have published a meta-ana-
lysis in which different indices of blood pressure to 
predict PIH have been comprehensively evaluated. 
This meta-analysis included 34 studies and evalu-
ated SBP, DBP, mean arterial pressure (MAP), and 
the increase over time in blood pressure. The data 
from this meta-analysis support the conclusion that 
blood pressure measurements in the first and second 
trimester have only a modest ability to predict hyper-
tensive disorders [32]. Therefore, in our research we 
focused our attention only on the third trimester of 
pregnancy. 
L-arginine is a semi-essential amino acid, and during 
pregnancy, under the circumstances of increased nitric ox-
ide production, endogenous synthesis is insufficient [33]. 
L-arginine concentrations have been demonstrated to 
be significantly reduced in women with PIH when 
compared with healthy women without the disease 
[34, 35].
The results of our study indicate that L-arginine 
might be a new diagnostic factor for pregnant women, 
which can help in quick diagnosis. Occurrence of PIH 
is associated with a significant reduction in plasma 
L-arginine concentration. The lower the concentra-
tion, the more advanced the pregnancy is. Although 
L-arginine may represent a promising diagnostic fac-
tor, there is currently limited information available to 
assess its diagnostic utility.
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Intracellular protein distribution induces the release 
of free amino acids, which are precursors for synthesis 
of other proteins. The intracellular pool of amino acids 
is in balance with the extracellular pool in plasma. This 
balance is regulated by membranous transport charac-
teristic of individual amino acids. Another source of 
extracellular pool is amino acids derived from dietary 
proteins [36]. 
L-arginine is a nutrient essential for foetal life and 
growth [37]. Battaglia et al. [38] have demonstrated 
that its oral administration (16 g/daily for 8 days) can 
enhance the uterine blood flow and ovarian response 
to gonadotropin, have beneficial effects on the en-
dometrium and increase the fertility of women with 
conception-related problems after in vitro procedures. 
Based on the findings of animal studies, numerous 
clinical trials were performed evaluating the effects of 
L-arginine on improvement of fertility and prevention 
of intrauterine growth restriction (IUGR) in pregnant 
women. Xiao and Li [39] have shown that daily intra-
venous infusion of L-arginine (20 g a day for 7 days) 
at the 33 week of pregnancy complicated by IUGR 
of unknown causes increased the foetal birth weight 
by 6.4%. Oral and intravenous L-arginine supple-
mentation involving healthy volunteers and pregnant 
women appears to be well tolerated, with no signifi-
cant adverse effects, even in doses as high as 20 g daily 
[40, 41]. Lampariello et al. [42], who administered 
oral L-arginine (6 g/day) to 43 pregnant women with 
IUGR, have observed significant clinical improvement 
in 32 cases and complete recovery in 19 pregnant 
women. Moreover, studies by Shen and Hu [43] have 
disclosed that L-arginine administered to women with 
IUGR decreases apoptosis in the placenta and substan-
tially improves the foetal growth and development. 
A meta-analysis of the data of seven clinical studies 
involving 916 patients has demonstrated that L-ar-
ginine supplementation can reduce diastolic blood 
pressure and prolong the physiological pregnancy and 
pregnancy complicated by hypertension with or with-
out proteinuria [44]. Based on the above findings, 
L-arginine can be considered to have beneficial effects 
on blood pressure regulation and can be used for quick 
diagnosis of pregnant women as well as prompt insti-
tution of appropriate treatment, including L-arginine 
supplementation. Our study showed a weak negative 
correlation between L-arginine concentration and SBP 
but not DBP. Literature data revealed that L-arginine 
could decrease DBP and SBP; however, a decline in 
SBP was not statistically significant [45]. It is possible 
because the high L-arginine leads to high nitric oxide 
synthesis resulting in blood pressure lowering and in-
versely.
Evidence specifically relating to the mechanistic ac-
tions of L-arginine in PIH is more limited. L-arginine is 
the most important NO donor [14]. Davidge et al. [46] 
estimated nitrate concentrations in women with PIH, 
indicating a reduction in the NO production com-
pared with healthy pregnant women.
Our findings show that plasma L-arginine concen-
tration is lower in the group with higher blood pres-
sure compared with physiological pregnancies. These 
results are confirmed by Kim et al. [34] and D’Aniello 
et al. [47]. 
Endothelial dysfunctions associated with impaired 
synthesis of NO are considered one of the causes of 
PIH. Cooke et al. [48] and Wu and Meininger [49] 
have found that administration of L-arginine to preg-
nant women increased the production of NO in the 
peripheral vessels and reduced blood pressure. More-
over, Wu and Meininger [49] and Wu et al. [19] have 
observed good outcomes using L-arginine for the 
treatment of arterial hypertension, hypertension-re-
lated pregnancy pathologies, ischaemic diseases, cir-
culatory failure, atherosclerosis, diabetes mellitus, 
glaucoma, cerebral stroke, vascular thrombosis, renal 
failure, liver dysfunction with urea cycle disorders and 
ammonia intoxications. L-arginine administered to 
women with PIH in the doses of 6 g/day normalised 
arterial blood pressure [50]. 
Conclusions
There is currently limited unequivocal informa-
tion available in literature about the evaluation of 
L-arginine levels in PIH diagnosis. The literature data 
give grounds for clinical use of L-arginine in prophy-
laxis and monitoring of metabolic diseases and arte-
rial hypertension whereas our findings indicate that 
quick detection of decreased plasma concentrations 
of L-arginine should enable earlier institution of ap-
propriate treatment of pregnant women, can prevent 
the development of fully symptomatic PIH or alle-
viate its course. This should improve the comfort of 
life and favourably affect proper foetal development. 
These benefits ought to be confirmed by larger and 
more-powered studies. 
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